Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 16/20 | 0.78 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15598648 | 1.00 | DOT1L (0.78) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16202797 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17307146 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15395666 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9970226 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17568778 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9942292 | 0.96 | DOT1L (0.79) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9970638 | 0.95 | DOT1L (0.76) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9970723 | 0.95 | DOT1L (0.75) | DOT1LDNMT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16705100 | 0.92 | DOT1L (0.67) | DOT1LDNMT1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| WO-2014153001-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | DOT1L 1/4885DNMT1 10/4885PI4KA 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.